Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.63 |
| ▸ | ACKR3 | P25106 | 3/20 | 0.56 |
| ▸ | MIF | P14174 | 3/20 | 0.52 |
| ▸ | ESRRA | P11474 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | MGLL | Q99685 | 1/20 | 0.47 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28542983 | 0.83 | RIPK1 (0.56) | RIPK1ACKR3MIFESRRAFAAH | |
| SCHEMBL21635351 | 0.83 | RIPK1 (0.56) | RIPK1ACKR3MIFESRRAFAAH | |
| SCHEMBL17883261 | 0.82 | RIPK1 (0.63) | RIPK1ACKR3MIFESRRAKDM4E | |
| SCHEMBL17883296 | 0.82 | RIPK1 (0.63) | RIPK1ACKR3MIFESRRANPC1 | |
| SCHEMBL73126 | 0.81 | RIPK1 (0.62) | RIPK1ACKR3MIFESRRANOTUM | |
| SCHEMBL17883253 | 0.77 | RIPK1 (0.58) | RIPK1ACKR3MIFESRRANOTUM | |
| SCHEMBL18646129 | 0.74 | ALDH1A1 (0.47) | ACKR3 | |
| SCHEMBL19691104 | 0.74 | ESRRA (0.63) | RIPK1ESRRAFAAHMGLLMAOA | |
| SCHEMBL69876 | 0.73 | ESRRA (0.62) | RIPK1MIFESRRAMAOANOTUM | |
| SCHEMBL27768462 | 0.73 | ESRRA (0.71) | RIPK1ESRRANOTUMCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12054478-B2 | Compositions and methods for inhibiting phenyl triazole MLL1-WDR5 protein-protein interaction | HUYABIO INTERNATIONAL, LLC (US) | 2024-08-06 | — | — | US | disclosed |
| US-20230098016-A1 | COMPOSITIONS AND METHODS FOR INHIBITING PHENYL TRIAZOLE MLL1-WDR5 PROTEIN-PROTEIN INTERACTION | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2023-03-30 | — | — | US | disclosed |
| US-11479545-B2 | Compositions and methods for inhibiting phenyl triazole MLL1-WDR5 protein-protein interaction | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2022-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12054478-B2 | Compositions and methods for inhibiting phenyl triazole MLL1-WDR5 protein-protein interaction | WDR5, MLLT1, WDR1 | RIPK1 308/4885ACKR3 4436/4885MIF 2823/4885 |
| US-20230098016-A1 | COMPOSITIONS AND METHODS FOR INHIBITING PHENYL TRIAZOLE MLL1-WDR5 PROTEIN-PROTEIN INTERACTION | WDR5, MLLT1, WDR1 | RIPK1 308/4885ACKR3 4436/4885MIF 2823/4885 |
| US-11479545-B2 | Compositions and methods for inhibiting phenyl triazole MLL1-WDR5 protein-protein interaction | WDR5, MLLT1, WDR1 | RIPK1 308/4885ACKR3 4436/4885MIF 2823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.